Dose-finding Study in Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed 59 enrolled Accenture

NaSingle-groupOpen-labelTreatment

Summary

* Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer. * Safety and efficacy study of GSK2110183 administered in combination with carboplatin and paclitaxel to subjects with platinum-resistant ovarian cancer.

Timeline

Start: 2012-11
Primary completion: 2015-07
Completion: 2015-11

Publications

Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clin Cancer Res. 2019 Mar 1;25(5):1472-1478. doi: 10.1158/1078-0432.CCR-18-2277. Epub 2018 Dec 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Afuresertib	Small molecule	50 mg	Oral
Subject	Afuresertib	Small molecule	125 mg	Oral
Subject	Afuresertib	Small molecule	150 mg	Oral
Background	Carboplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Indications

No indication recorded.